Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Extension Study of CSJ117 (Ecleralimab) in Adult Asthma
NCT04946318Phase 2Terminated
- Sponsor
- Novartis
- Start
- Sep 2021
- Primary completion
- Sep 2022
- Modality
- Antibody Conjugates, Fab Fragments, Monoclonal Antibodies
- Countries
- 14
01
Overview
Phase 2, randomised, double-blind trial of ecleralimab in asthma (6 arms), sponsored by Novartis. Primary endpoints: Number of treatment emergent adverse events (AEs) and serious adverse events (SAEs) up to 40 weeks and Number of treatment emergent participant deaths and participant hospitalizations up to 40 weeks. Started Sep 2021; status: terminated.
02
Drugs
ecleralimab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT04946318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04946318.